NO2785538T3 - - Google Patents

Info

Publication number
NO2785538T3
NO2785538T3 NO12794266A NO12794266A NO2785538T3 NO 2785538 T3 NO2785538 T3 NO 2785538T3 NO 12794266 A NO12794266 A NO 12794266A NO 12794266 A NO12794266 A NO 12794266A NO 2785538 T3 NO2785538 T3 NO 2785538T3
Authority
NO
Norway
Application number
NO12794266A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2785538T3 publication Critical patent/NO2785538T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/20Animal model comprising regulated expression system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0368Animal model for inflammation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0393Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO12794266A 2014-05-07 2012-11-22 NO2785538T3 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989757P 2014-05-07 2014-05-07

Publications (1)

Publication Number Publication Date
NO2785538T3 true NO2785538T3 (en:Method) 2018-08-04

Family

ID=53284509

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12794266A NO2785538T3 (en:Method) 2014-05-07 2012-11-22

Country Status (26)

Country Link
US (7) US9565841B2 (en:Method)
EP (3) EP3906781A1 (en:Method)
JP (5) JP6640740B2 (en:Method)
KR (2) KR102517112B1 (en:Method)
CN (2) CN106470545B (en:Method)
AU (3) AU2015255977B2 (en:Method)
BR (1) BR112016025745A2 (en:Method)
CA (2) CA2947307C (en:Method)
CY (2) CY1119773T1 (en:Method)
DK (2) DK3027015T3 (en:Method)
ES (2) ES2887852T3 (en:Method)
HR (2) HRP20180242T1 (en:Method)
HU (2) HUE055860T2 (en:Method)
IL (3) IL248358B2 (en:Method)
LT (2) LT3027015T (en:Method)
MX (1) MX370672B (en:Method)
NO (1) NO2785538T3 (en:Method)
PH (1) PH12016502058A1 (en:Method)
PL (2) PL3281521T3 (en:Method)
PT (2) PT3281521T (en:Method)
RS (2) RS62345B1 (en:Method)
RU (1) RU2703139C2 (en:Method)
SG (2) SG11201608570YA (en:Method)
SI (2) SI3281521T1 (en:Method)
SM (2) SMT202100560T1 (en:Method)
WO (1) WO2015171861A1 (en:Method)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2785538T3 (en:Method) * 2014-05-07 2018-08-04
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
PL3212819T3 (pl) * 2014-09-17 2023-10-16 Oerlikon Surface Solutions Ag, Pfäffikon Sposób wytwarzania narzędzia skrawającego powleczonego podwójną warstwą o polepszonej odporności na zużycie
MX2017006802A (es) 2014-11-24 2018-01-30 Regeneron Pharma Animales no humanos que expresan el complejo cd3 humanizado.
WO2016089692A1 (en) 2014-12-05 2016-06-09 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
CA2968675C (en) 2014-12-09 2023-10-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
US10306874B2 (en) 2015-11-20 2019-06-04 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
MX2018009513A (es) 2016-02-04 2019-01-31 Regeneron Pharma Animales no humanos que tienen un gen angptl8 modificado genéticamente.
EP3422845B1 (en) * 2016-02-29 2021-06-02 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
ES2962277T3 (es) 2017-09-29 2024-03-18 Regeneron Pharma Roedores que comprenden un locus Ttr humanizado y métodos de uso
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
JP7048051B2 (ja) 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
AU2019308205B2 (en) 2018-07-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
WO2020074005A1 (en) * 2018-10-12 2020-04-16 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric genes
CN114164177A (zh) * 2019-01-17 2022-03-11 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
EP3801011A1 (en) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
CN112300265B (zh) * 2019-07-29 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il33基因人源化的非人动物的构建方法和应用
CN112430621B (zh) * 2019-08-09 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il2ra基因人源化的非人动物的构建方法及应用
CN112779285B (zh) * 2019-11-11 2023-01-06 百奥赛图(北京)医药科技股份有限公司 人源化il-10和il-10ra基因改造动物的构建方法和应用
CN114786479B (zh) * 2019-12-25 2023-12-15 江苏集萃药康生物科技股份有限公司 一种il-15人源化小鼠模型及其用途
CA3169272A1 (en) * 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
CN111149767B (zh) * 2020-02-24 2021-07-20 中南大学湘雅二医院 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN111808882B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用
CN111793646B (zh) * 2020-09-08 2021-01-15 北京百奥赛图基因生物技术有限公司 Il1r1基因人源化改造的非人动物的构建方法及其应用
CN111926039B (zh) * 2020-09-23 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Il-13基因人源化的非人动物的构建方法和应用
CN116802200A (zh) * 2020-12-21 2023-09-22 瑞泽恩制药公司 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物
CN114835798B (zh) * 2021-05-28 2024-02-23 百奥赛图(北京)医药科技股份有限公司 Cd36基因人源化非人动物的构建方法及应用
WO2024067796A1 (zh) * 2022-09-28 2024-04-04 百奥赛图(北京)医药科技股份有限公司 一种il5和/或il5ra基因人源化修饰的非人动物
JP2026502506A (ja) * 2023-01-11 2026-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 規制に準拠した自動化されたアッセイのためのシステム及び方法
WO2025175099A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. A rodent copd model

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
JP2007252370A (ja) * 2006-02-22 2007-10-04 Institute Of Physical & Chemical Research Il−4初期発現系トランスジェニック非ヒト動物およびその利用
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
EP2449094A4 (en) * 2009-06-29 2013-07-10 Qingfeng Chen METHOD FOR PRODUCING HUMANIZED NON-MAMMAL MAMMALS
JP2013500018A (ja) * 2009-07-24 2013-01-07 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー ゲノム編集のための方法
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
EP3375284B1 (en) * 2011-02-15 2023-03-29 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice and uses thereof
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
HUE033400T2 (en) * 2011-10-28 2017-12-28 Regeneron Pharma Humanized IL-6 and IL-6 receptor
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
KR102307248B1 (ko) * 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CA2881468C (en) 2012-09-07 2023-03-21 Yale University Genetically modified mice which express human cytokines and methods of use thereof, including engraftment
NZ724353A (en) 2012-11-05 2022-05-27 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
JP6444895B2 (ja) 2013-02-20 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化t細胞補助受容体を発現するマウス
DK2958937T3 (en) 2013-02-22 2018-11-26 Regeneron Pharma Mice expressing humanized major histocompatibility complex
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI2908626T1 (sl) 2013-10-15 2017-02-28 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
SG10201900003WA (en) 2013-11-19 2019-02-27 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
AU2014353347B2 (en) 2013-11-19 2020-07-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
SG11201604886WA (en) 2014-04-08 2016-07-28 Regeneron Pharma Non-human animals having humanized fc-gamma receptors
SG11201608696RA (en) 2014-05-05 2016-11-29 Regeneron Pharma Humanized c5 and c3 animals
NO2785538T3 (en:Method) 2014-05-07 2018-08-04

Also Published As

Publication number Publication date
JP6640740B2 (ja) 2020-02-05
US12310340B2 (en) 2025-05-27
RU2016143376A (ru) 2018-06-09
JP2024159985A (ja) 2024-11-08
IL297105B2 (en) 2024-01-01
NZ725615A (en) 2024-05-31
AU2021218060C1 (en) 2024-11-07
AU2015255977B2 (en) 2021-09-02
AU2021218060A1 (en) 2021-09-09
DK3027015T3 (en) 2018-01-22
HUE055860T2 (hu) 2021-12-28
PT3027015T (pt) 2018-02-09
KR102517112B1 (ko) 2023-04-03
IL304841B2 (en) 2026-01-01
JP6838131B2 (ja) 2021-03-03
US20150320021A1 (en) 2015-11-12
US10477842B2 (en) 2019-11-19
US11109578B2 (en) 2021-09-07
AU2015255977A1 (en) 2016-11-17
MX370672B (es) 2019-12-19
KR102473565B1 (ko) 2022-12-02
US20150320022A1 (en) 2015-11-12
RU2703139C2 (ru) 2019-10-15
CA2947307C (en) 2023-09-26
US11963521B2 (en) 2024-04-23
IL304841A (en) 2023-09-01
CN110269047A (zh) 2019-09-24
US20170311580A1 (en) 2017-11-02
EP3281521A1 (en) 2018-02-14
EP3027015A1 (en) 2016-06-08
CA3207834A1 (en) 2015-11-12
US9565841B2 (en) 2017-02-14
US20180000056A1 (en) 2018-01-04
CY1124605T1 (el) 2022-07-22
IL248358B2 (en) 2023-03-01
HRP20211455T1 (hr) 2022-01-07
IL297105A (en) 2022-12-01
US20200022344A1 (en) 2020-01-23
LT3027015T (lt) 2018-01-25
PH12016502058A1 (en) 2017-01-09
AU2024204694A1 (en) 2024-09-05
RU2019131253A (ru) 2019-12-06
SI3281521T1 (sl) 2021-11-30
CN106470545A (zh) 2017-03-01
PT3281521T (pt) 2021-09-16
PL3281521T3 (pl) 2022-01-03
CN106470545B (zh) 2019-08-20
EP3906781A1 (en) 2021-11-10
JP2020058379A (ja) 2020-04-16
SI3027015T1 (en) 2018-02-28
US9743647B2 (en) 2017-08-29
SMT201800018T1 (it) 2018-03-08
LT3281521T (lt) 2021-09-27
IL248358A0 (en) 2016-11-30
IL297105B1 (en) 2023-09-01
CN110269047B (zh) 2021-11-02
CA2947307A1 (en) 2015-11-12
JP2022171841A (ja) 2022-11-11
EP3027015B1 (en) 2017-11-08
US10588298B2 (en) 2020-03-17
WO2015171861A1 (en) 2015-11-12
SMT202100560T1 (it) 2021-11-12
HUE038028T2 (hu) 2018-09-28
SG11201608570YA (en) 2016-11-29
EP3281521B1 (en) 2021-06-30
JP2017514501A (ja) 2017-06-08
CY1119773T1 (el) 2018-06-27
KR20220165814A (ko) 2022-12-15
HRP20180242T1 (hr) 2018-03-09
ES2656529T3 (es) 2018-02-27
US20210368753A1 (en) 2021-12-02
ES2887852T3 (es) 2021-12-28
DK3281521T3 (da) 2021-09-20
BR112016025745A2 (pt) 2018-01-16
AU2021218060B2 (en) 2024-04-11
MX2016014563A (es) 2017-02-23
NZ763861A (en) 2024-05-31
SG10201912354PA (en) 2020-02-27
IL248358B (en) 2022-11-01
JP7755699B2 (ja) 2025-10-16
RS62345B1 (sr) 2021-10-29
RU2016143376A3 (en:Method) 2018-11-22
JP7145250B2 (ja) 2022-09-30
KR20160150637A (ko) 2016-12-30
IL304841B1 (en) 2025-09-01
US20230027494A1 (en) 2023-01-26
JP2021087434A (ja) 2021-06-10
CA3207834C (en) 2025-10-14
PL3027015T3 (pl) 2018-04-30
RS57073B1 (sr) 2018-06-29

Similar Documents

Publication Publication Date Title
BR112014017635A2 (en:Method)
BR112014017614A2 (en:Method)
BR112014017625A2 (en:Method)
BR112014017659A2 (en:Method)
BR112014017592A2 (en:Method)
BR112014017607A2 (en:Method)
BR112014017646A2 (en:Method)
BR112014018648A2 (en:Method)
BR112014017638A2 (en:Method)
BR112014018115A2 (en:Method)
BR112014017609A2 (en:Method)
BR112014024237A2 (en:Method)
BR112014017644A2 (en:Method)
BR112014017634A2 (en:Method)
BR112014017618A2 (en:Method)
BR112014017647A2 (en:Method)
BR112014017623A2 (en:Method)
BR112014017630A2 (en:Method)
BR112014017627A2 (en:Method)
BR112014017652A2 (en:Method)
BR112014017631A2 (en:Method)
BR112014017641A2 (en:Method)
BR112014025138A2 (en:Method)
BR112014023519A2 (en:Method)
BR112014018787A2 (en:Method)